Nanox Imaging Ltd. (NASDAQ: NNOX), a company focused on transforming medical imaging through affordable technology and AI-driven solutions, announced it will report its second-quarter 2026 financial results before market open on September 9, 2026. The announcement comes as the company continues to advance its integrated platform aimed at expanding access to preventive healthcare worldwide.
CEO and Acting Chairman Erez Meltzer and CFO Guy Nathanzon will host a conference call at 8:30 a.m. ET on the same day to review the results and provide a business update. A live webcast will be available through the Investor Relations section of the Nanox website, offering stakeholders real-time access to the discussion. The full press release is available at https://ibn.fm/y877D.
Nanox is building an end-to-end medical imaging and healthcare services platform that combines affordable imaging hardware, AI-based analytics, cloud-based software, remote radiology access, and health IT solutions. The company’s ecosystem includes several key components: Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis system designed for scalability; Nanox.AI, which uses algorithms to augment CT imaging interpretation for early signs of chronic disease; Nanox.CLOUD, a secure platform for data management and advanced imaging analytics; and Nanox.MARKETPLACE, along with USARAD Holdings, providing teleradiology services. Additionally, Nanox Health IT offers RIS, PACS, AI, dictation, and secure infrastructure solutions to streamline clinical workflows.
The integration of these technologies is intended to lower barriers to adoption, improve utilization, and advance preventive care, particularly outside traditional hospital settings. By leveraging proprietary digital X-ray technology and AI-driven analytics, Nanox aims to enhance the efficiency of routine imaging workflows, support early disease detection, and improve patient outcomes. The company’s vision is to make medical imaging more accessible and seamless from scan to interpretation.
The upcoming financial results will provide investors and industry observers with insights into Nanox’s progress in commercializing its platform and its financial trajectory. The conference call will likely address adoption rates, partnerships, and regulatory milestones, which are critical for a company operating in the highly regulated medical device sector. For business leaders, Nanox’s approach represents a shift toward preventive, value-based care, potentially reducing long-term healthcare costs by enabling earlier intervention.
The broader impact of Nanox’s technology could be significant: if successful, it might democratize access to advanced imaging in underserved regions and lower the cost of diagnostic procedures. However, the company faces challenges including regulatory hurdles, competition from established imaging giants, and the need to prove clinical efficacy. The Q2 results will be a key indicator of whether Nanox is gaining traction in a market that is increasingly embracing digital health and AI.
Investors and stakeholders can access the latest news and updates on Nanox at the company’s newsroom at http://ibn.fm/NNOX. As the healthcare industry continues to evolve, Nanox’s performance will be closely watched for signals of how AI and cloud-based solutions can transform medical imaging and preventive care delivery.
